Dis­con­tin­u­a­tion day: Third Har­mon­ic’s on­ly drug fails safe­ty study as BioCryst culls pipeline af­ter ASH

Third Har­mon­ic Bio is call­ing it quits on its lead tri­al just three months af­ter be­ing one of the few biotech IPOs this year, and BioCryst is ax­ing a rare blood dis­ease can­di­date af­ter No­var­tis pre­sent­ed block­buster-best­ing da­ta at the Amer­i­can So­ci­ety of Hema­tol­ogy this week.

Na­tal­ie Holles’ Third Har­mon­ic is dis­con­tin­u­ing a Phase Ib of its KIT in­hibitor THB001 “af­ter ob­serv­ing asymp­to­matic liv­er transamini­tis in two sub­jects en­rolled in the first dose co­hort of 200mg BID,” the biotech said Thurs­day morn­ing. The biotech is look­ing at find­ing a new oral wild-type KIT in­hibitor, with “mul­ti­ple can­di­date mol­e­cules” un­der­go­ing tox­i­col­o­gy stud­ies, so a new in­ves­ti­ga­tion­al can­di­date can be se­lect­ed next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER